Dr. Robbie Majzner's laboratory focuses on engineering CAR T cells and other immunotherapeutics for children with cancer. Dr. Majzner has generated and optimized novel receptors to recognize antigens over-expressed on pediatric solid tumors such as GD2, B7-H3, and ALK. Current work focuses on imparting multi-specificity to CAR T cells and optimizing these receptors to enhance their efficacy when the amount of target (antigen density) is limiting. By drawing on state of the art bioengineering techniques, the Majzner laboratory focuses on enhancing the potency and specificity of CAR T cells for children with cancer.

Clinically, Dr. Majzner cares for all patients with neuroblastoma at the Lucile Packard Children's Hospital and has a specific interest in bringing novel immunotherapies to clinical trials for these patients and those with other solid tumors.